On January 19, the UK changes the paperwork rules.
Before, if a listed company wanted to issue more than about one fifth more shares, it usually had to do a full prospectus. That prospectus is slow and gives the market lots of advance warning.
After January 19, that threshold jumps. A company can issue a lot more new shares, up to about three quarters of what is already out there, before a full prospectus is required.
But the UK did not remove the runway check. If a company does need a prospectus, it still has to include a working capital statement saying it has enough money to operate for at least the next 12 months, or explain the shortfall.
So the gate is still real, meaning the company still has to prove it can fund itself.
What changes is how often the company gets forced into the slowest, most telegraphed paperwork. For many follow on raises, the big prospectus process becomes less common, which means less delay and fewer weeks for shorts to front run the financing.
Here is the part that matters. This only really unlocks after approval.
Approval is the switch that turns NWBO from a survival story into a financeable asset. Before approval, every funding conversation is discounted because the buyer is underwriting uncertainty. After approval, the buyer is underwriting a commercial product and a manufacturing plan. That changes who can invest, how much they can invest, and what terms they demand.
It also answers the working capital question. A company does not need to already have 12 months of cash sitting idle. It needs to be able to show 12 months of runway using cash on hand plus committed funding. The cleanest way to do that is a partnership. If a partner commits cash up front, commits an equity investment, or commits milestone payments tied to approval, that is real money that can be modeled and counted. That is how the 12 month statement becomes supportable.
This is also where Advent BioServices matters. Owning Advent turns manufacturing from a vendor risk into owned infrastructure. It reduces execution risk, improves diligence, and makes a partner more willing to commit capital because the manufacturing node is inside the company. It can also improve the group cash picture through contracts and receivables once commercialization begins.
And there is one more execution tool already in place on the US side. NWBO has an effective 250 million dollar shelf registration. A shelf does not give them cash automatically. It gives them speed. It means that if approval or a partner check creates demand, the company can raise capital quickly through an already registered pathway instead of spending months setting up new paperwork. That also shrinks the window shorts like to trade against.
So the logic is simple and it matches what ilovetech has been saying.
Approval is the unlock. The January 19 rule change reduces the time tax once the unlock happens. The 250 million shelf provides a fast US execution lane. Advent reduces manufacturing and diligence risk. Together they shorten the window between plan and execution, which is exactly the window the OTC short trade has been living on.
Bullish
Market Data 
Markets 
AI
